PMID- 30150003
OWN - NLM
STAT- MEDLINE
DCOM- 20190501
LR  - 20200103
IS  - 1876-4754 (Electronic)
IS  - 1935-861X (Print)
IS  - 1876-4754 (Linking)
VI  - 11
IP  - 6
DP  - 2018 Nov-Dec
TI  - BDNF genotype and tDCS interaction in aphasia treatment.
PG  - 1276-1281
LID - S1935-861X(18)30292-4 [pii]
LID - 10.1016/j.brs.2018.08.009 [doi]
AB  - BACKGROUND: Several studies, including a randomized controlled trial by our 
      group, support applying anodal tDCS (A-tDCS) to the left hemisphere during 
      behavioral aphasia treatment to improve outcomes. A clear mechanism explaining 
      A-tDCS's efficacy has not been established, but modulation of neuroplasticity may 
      be involved. OBJECTIVE/HYPOTHESIS: The brain-derived neurotrophic factor (BDNF) 
      gene influences neuroplasticity and may modulate the effects of tDCS. Utilizing 
      data from our recently completed trial, we conducted a planned test of whether 
      aphasia treatment outcome is influenced by interaction between A-tDCS and a 
      single-nucleotide polymorphism of the BDNF gene, rs6265. METHODS: Seventy-four 
      individuals with chronic stroke-induced aphasia completed 15 language therapy 
      sessions and were randomized to receive 1 mA A-tDCS or sham tDCS (S-tDCS) to the 
      intact left temporoparietal region for the first 20 min of each session. BDNF 
      genotype was available for 67 participants: 37 participants had the typical 
      val/val genotype. The remaining 30 participants had atypical BDNF genotype 
      (Met allele carriers). The primary outcome factor was improvement in object 
      naming at 1 week after treatment completion. Maintenance of treatment effects was 
      evaluated at 4 and 24 weeks. RESULTS: An interaction was revealed between tDCS 
      condition and genotype for treatment-related naming improvement (F = 4.97, 
      p = 0.03). Participants with val/val genotype who received A-tDCS showed greater 
      response to aphasia treatment than val/val participants who received S-tDCS, as 
      well as the Met allele carriers, regardless of tDCS condition. CONCLUSION: 
      Individuals with the val/val BDNF genotype are more likely to benefit from A-tDCS 
      during aphasia treatment.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Fridriksson, Julius
AU  - Fridriksson J
AD  - Department of Communication Sciences & Disorders, University of South Carolina, 
      USA. Electronic address: jfridrik@sc.edu.
FAU - Elm, Jordan
AU  - Elm J
AD  - Department of Public Health Sciences, Medical University of South Carolina, USA.
FAU - Stark, Brielle C
AU  - Stark BC
AD  - Department of Communication Sciences & Disorders, University of South Carolina, 
      USA.
FAU - Basilakos, Alexandra
AU  - Basilakos A
AD  - Department of Communication Sciences & Disorders, University of South Carolina, 
      USA.
FAU - Rorden, Chris
AU  - Rorden C
AD  - Department of Psychology, University of South Carolina, USA.
FAU - Sen, Souvik
AU  - Sen S
AD  - Department of Neurology, University of South Carolina, USA.
FAU - George, Mark S
AU  - George MS
AD  - Department of Psychiatry, Medical University of South Carolina, USA; Department 
      of Neurology, Medical University of South Carolina, USA; Ralph H. Johnson VA 
      Medical Center, Charleston, USA.
FAU - Gottfried, Michelle
AU  - Gottfried M
AD  - Department of Public Health Sciences, Medical University of South Carolina, USA.
FAU - Bonilha, Leonardo
AU  - Bonilha L
AD  - Department of Neurology, Medical University of South Carolina, USA.
LA  - eng
GR  - P20 GM109040/GM/NIGMS NIH HHS/United States
GR  - P50 DC014664/DC/NIDCD NIH HHS/United States
GR  - T32 DC014435/DC/NIDCD NIH HHS/United States
GR  - U01 DC011739/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20180818
PL  - United States
TA  - Brain Stimul
JT  - Brain stimulation
JID - 101465726
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adult
MH  - Aphasia/diagnosis/*genetics/*therapy
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Female
MH  - *Genotype
MH  - Humans
MH  - Language Therapy/trends
MH  - Male
MH  - Middle Aged
MH  - Photic Stimulation/methods
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Psychomotor Performance/physiology
MH  - Stroke/diagnosis/genetics/therapy
MH  - Transcranial Direct Current Stimulation/*methods
MH  - Treatment Outcome
PMC - PMC6293970
MID - NIHMS1504951
OTO - NOTNLM
OT  - Aphasia
OT  - Aphasia treatment
OT  - Electrical brain stimulation
OT  - Rehabilitation
OT  - Stroke
OT  - tDCS
COIS- Conflicts of interest The authors report no conflicts of interest with this work.
EDAT- 2018/08/29 06:00
MHDA- 2019/05/02 06:00
PMCR- 2019/11/01
CRDT- 2018/08/29 06:00
PHST- 2018/05/23 00:00 [received]
PHST- 2018/08/13 00:00 [revised]
PHST- 2018/08/14 00:00 [accepted]
PHST- 2018/08/29 06:00 [pubmed]
PHST- 2019/05/02 06:00 [medline]
PHST- 2018/08/29 06:00 [entrez]
PHST- 2019/11/01 00:00 [pmc-release]
AID - S1935-861X(18)30292-4 [pii]
AID - 10.1016/j.brs.2018.08.009 [doi]
PST - ppublish
SO  - Brain Stimul. 2018 Nov-Dec;11(6):1276-1281. doi: 10.1016/j.brs.2018.08.009. Epub 
      2018 Aug 18.